Secukinumab Shows Benefit for Hidradenitis Suppurativa at 1 Year

Currently, the tumor necrosis factor inhibitor adalimumab is the only biologic therapy approved for the treatment of moderate to severe hidradenitis suppurativa.

Related Keywords

Boston ,Massachusetts ,United States ,Washington ,Adam Friedman ,Alexab Kimball ,European Academy Of Dermatology ,Pfizer ,George Washington University ,Beth Israel Deaconess Medical Center ,Harvard Medical School ,Novartis ,European Academy ,Global Assessment ,Skin Pain Numeric Rating Scale ,Skin And Soft Tissue Infection ,Hidradenitis Suppurativa ,Biologic Therapy ,Tumor ,Europe ,European ,Imbalance ,Spain ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Clinical Research ,Clinical Trials ,Linical Studies ,Interleukins ,Match ,Match Day ,Watch Application ,Atch Medical Students ,Common Cold ,Cute Nasopharyngitis ,Pain Management ,Psoriasis ,Headache ,Healthcare And ,